Michael C Donegan sold $8,621 of TXMD
Prin. Fin. and Acctg. Officer at TherapeuticsMD, Inc.. 1,697 shares at an average of $5.08, traded Jan 26, 2023, filed Jan 30, 2023.
Score components
- +15RoleOfficer
- 0Trade size$9k at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-005554, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 26, 2023 | MOption exercise Common Stock | +2,400 | $0.00 | $0 | 10,010 | Jan 30, 2023 |
| Jan 26, 2023 | MOption exercise Common Stock | +2,400 | $0.00 | $0 | 12,410 | Jan 30, 2023 |
| Jan 26, 2023 | MOption exercise Common Stock | +1,140 | $0.00 | $0 | 13,550 | Jan 30, 2023 |
| Jan 26, 2023 | SOpen-market sale Common Stock | -1,648 | $5.08 | $8,371 | 11,902 | Jan 30, 2023 |
| Jan 27, 2023 | SOpen-market sale Common Stock | -49 | $5.09 | $249 | 11,853 | Jan 30, 2023 |
| Jan 26, 2023 | MOption exercise Performance Stock Unitsderivative | -2,400 | $0.00 | $0 | 0 | Jan 30, 2023 |
| Jan 26, 2023 | MOption exercise Performance Stock Unitsderivative | -2,400 | $0.00 | $0 | 0 | Jan 30, 2023 |
| Jan 26, 2023 | MOption exercise Performance Stock Unitsderivative | -1,140 | $0.00 | $0 | 0 | Jan 30, 2023 |
Related signals
Other insiders at TherapeuticsMD, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | TXMDbuy TherapeuticsMD, Inc. | Tommy G Thompson director | $14k 8,400 shares | +57% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $489 490 shares | +1% | |
| 23Weak | TherapeuticsMD, Inc. | Tommy G Thompson director | $326 325 shares | +2% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $1,994 2,303 shares | +3% | |
| 31Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $7,099 4,094 shares | +9% | |
| 23Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $2,039 1,200 shares | +3% | |
| 21Weak | TXMDsell TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $44k 19,050 shares | -23% | |
| 5Weak | TXMDsell TherapeuticsMD, Inc. | Michael C Donegan Prin. Fin. and Acctg. Officer | $6,988 1,309 shares | -15% | |
| 24Weak | TXMDbuy TherapeuticsMD, Inc. | Rubric Capital Management LP owner | $90k 14,825 shares | +1% | |
| 30Weak | TherapeuticsMD, Inc. | Brian Bernick Co-Chief Executive Officer | $6,621 1,255 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.